RELATED CONTENT
NEWS
- NICE says no to GSK's Tyverb and Roche's Herceptin, again
- NICE no for Tyverb and Herceptin in breast cancer, Roche considers appeal
- "Step change" Yervoy from BMS not cost effective for NICE: may need biomarker test
- Scots choose chewy Lipitor but refuse Zytiga, Sycrest and Gilenya
ANALYSIS
Other Informa Analysis
EVENTS
Today
The Rembrandt Hotel, London
07 June 2012
The Rembrandt Hotel, London
12 June 2012
Annecy, France
JOB OF THE WEEK

Section Head (m/f)
DRA International/CIS Section

Section Head (m/f)
DRA International/CIS Section

